Cargando…
330. Outpatient Parenteral Antimicrobial Therapy in People who Inject Drugs
BACKGROUND: People with opioid use disorder (OUD) make up a significant and increasing proportion patients requiring outpatient parenteral antimicrobial therapy (OPAT). Many of these patients do not receive OUD treatment during their index hospitalization, leading to missed opportunities for treatme...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677293/ http://dx.doi.org/10.1093/ofid/ofad500.401 |
_version_ | 1785150095556083712 |
---|---|
author | Hawes, Armani Yanek, Lisa Buresh, Megan E Bodnar, Alia Keller, Sara C |
author_facet | Hawes, Armani Yanek, Lisa Buresh, Megan E Bodnar, Alia Keller, Sara C |
author_sort | Hawes, Armani |
collection | PubMed |
description | BACKGROUND: People with opioid use disorder (OUD) make up a significant and increasing proportion patients requiring outpatient parenteral antimicrobial therapy (OPAT). Many of these patients do not receive OUD treatment during their index hospitalization, leading to missed opportunities for treatment, recurrent hospitalizations, worse outcomes, and increased costs. We describe predictors of addiction medicine consultation among people with OUD requiring OPAT, and the impact of addiction medicine consultation on receipt of medications for opioid use disorder (MOUD) after discharge. METHODS: We reviewed records from 172 patients with OUD who were discharged on OPAT from Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center 4/2020-9/2022. We described differences between those who received and did not receive inpatient addiction medicine consults by demographics, service (medicine vs surgical), type of insurance, type of infection, disposition, and addiction treatment. RESULTS: The addiction medicine team was consulted for 120 patients and was not consulted for 46 patients. Addiction medicine was more likely to be consulted on younger patients (43.3 years vs 48.3 years, p=0.01), for patients with endovascular infections (23.3% vs 2.3%, p< 0.01) or bloodstream infections (31.9% vs 13.6%, p=0.02), and when the infectious organism was methicillin-resistant Staphylococcus aureus (40.7% vs 20.9%, p=0.02). When the addiction medicine team was consulted, patients were more likely to be discharged on MOUD, specifically buprenorphine (32.5% vs 17.4%, p< 0.01) or methadone (57.5% vs 39.1%, p< 0.01). Overall, most patients were discharged to a skilled nursing facility (SNF), but patients who received addiction medicine team consult were more likely to be discharged to SNF than home (92.9% vs 7.0%, p< 0.01). Patients discharged to SNF were less likely to have a 30 day readmission compared to patients discharged home (14.4% vs 32.0%, p=0.03). [Figure: see text] CONCLUSION: Addiction medicine consultations were associated with an increased likelihood of evidence-based MOUD among patients with OUD requiring OPAT. By maximizing the resources of the addiction medicine team, we hope to improve outcomes for patients with opioid use disorder who require OPAT. DISCLOSURES: Sara C. Keller, MD, MPH, MSPH, Pfizer: Advisor/Consultant |
format | Online Article Text |
id | pubmed-10677293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106772932023-11-27 330. Outpatient Parenteral Antimicrobial Therapy in People who Inject Drugs Hawes, Armani Yanek, Lisa Buresh, Megan E Bodnar, Alia Keller, Sara C Open Forum Infect Dis Abstract BACKGROUND: People with opioid use disorder (OUD) make up a significant and increasing proportion patients requiring outpatient parenteral antimicrobial therapy (OPAT). Many of these patients do not receive OUD treatment during their index hospitalization, leading to missed opportunities for treatment, recurrent hospitalizations, worse outcomes, and increased costs. We describe predictors of addiction medicine consultation among people with OUD requiring OPAT, and the impact of addiction medicine consultation on receipt of medications for opioid use disorder (MOUD) after discharge. METHODS: We reviewed records from 172 patients with OUD who were discharged on OPAT from Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center 4/2020-9/2022. We described differences between those who received and did not receive inpatient addiction medicine consults by demographics, service (medicine vs surgical), type of insurance, type of infection, disposition, and addiction treatment. RESULTS: The addiction medicine team was consulted for 120 patients and was not consulted for 46 patients. Addiction medicine was more likely to be consulted on younger patients (43.3 years vs 48.3 years, p=0.01), for patients with endovascular infections (23.3% vs 2.3%, p< 0.01) or bloodstream infections (31.9% vs 13.6%, p=0.02), and when the infectious organism was methicillin-resistant Staphylococcus aureus (40.7% vs 20.9%, p=0.02). When the addiction medicine team was consulted, patients were more likely to be discharged on MOUD, specifically buprenorphine (32.5% vs 17.4%, p< 0.01) or methadone (57.5% vs 39.1%, p< 0.01). Overall, most patients were discharged to a skilled nursing facility (SNF), but patients who received addiction medicine team consult were more likely to be discharged to SNF than home (92.9% vs 7.0%, p< 0.01). Patients discharged to SNF were less likely to have a 30 day readmission compared to patients discharged home (14.4% vs 32.0%, p=0.03). [Figure: see text] CONCLUSION: Addiction medicine consultations were associated with an increased likelihood of evidence-based MOUD among patients with OUD requiring OPAT. By maximizing the resources of the addiction medicine team, we hope to improve outcomes for patients with opioid use disorder who require OPAT. DISCLOSURES: Sara C. Keller, MD, MPH, MSPH, Pfizer: Advisor/Consultant Oxford University Press 2023-11-27 /pmc/articles/PMC10677293/ http://dx.doi.org/10.1093/ofid/ofad500.401 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Hawes, Armani Yanek, Lisa Buresh, Megan E Bodnar, Alia Keller, Sara C 330. Outpatient Parenteral Antimicrobial Therapy in People who Inject Drugs |
title | 330. Outpatient Parenteral Antimicrobial Therapy in People who Inject Drugs |
title_full | 330. Outpatient Parenteral Antimicrobial Therapy in People who Inject Drugs |
title_fullStr | 330. Outpatient Parenteral Antimicrobial Therapy in People who Inject Drugs |
title_full_unstemmed | 330. Outpatient Parenteral Antimicrobial Therapy in People who Inject Drugs |
title_short | 330. Outpatient Parenteral Antimicrobial Therapy in People who Inject Drugs |
title_sort | 330. outpatient parenteral antimicrobial therapy in people who inject drugs |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677293/ http://dx.doi.org/10.1093/ofid/ofad500.401 |
work_keys_str_mv | AT hawesarmani 330outpatientparenteralantimicrobialtherapyinpeoplewhoinjectdrugs AT yaneklisa 330outpatientparenteralantimicrobialtherapyinpeoplewhoinjectdrugs AT bureshmegane 330outpatientparenteralantimicrobialtherapyinpeoplewhoinjectdrugs AT bodnaralia 330outpatientparenteralantimicrobialtherapyinpeoplewhoinjectdrugs AT kellersarac 330outpatientparenteralantimicrobialtherapyinpeoplewhoinjectdrugs |